Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2026
Pharma News, 2026
FDA grants Supernus 7-year market exclusivity for Parkinson's drug
Supernus Pharmaceuticals announced seven years of FDA market exclusivity for ONAPGO (apomorphine HCl), a device for advanced Parkinson's disease treatment.
313TE targets IL-13Rα2-positive tumors in preclinical testing
A novel T-cell engager, 313TE, demonstrated significant anti-tumor activity against IL-13Rα2-positive cells in preclinical models, showing therapeutic potential.
FDA Grants Accelerated Approval to Jemperli for Rectal Cancer Subset
The FDA has granted accelerated approval for GSK's Jemperli as a treatment for adults with MSI-H/dMMR locally advanced rectal cancer, based on AZUR-1 trial data.
Faeth to Present Preclinical Data on PIKTOR in HR+/HER2- Breast Cancer Models
Faeth Therapeutics will showcase preclinical data for PIKTOR at ESMO 2026, detailing its efficacy in HR+/HER2- breast cancer models as a monotherapy and combo.
Study identifies initial cellular events in autoimmune kidney inflammation
Researchers from the University of Osaka have mapped the early cellular events that trigger inflammation in ANCA-associated glomerulonephritis.
Symposium Highlights MIT’s Wide Range of Innovations for Aging Brain Health
An MIT symposium showcased diverse innovations for aging brain health, highlighting advances in AI, tissue engineering, and novel chemical probes.
Enlivex Lays Off 60% of Staff, Pauses Preclinical R&D to Focus on Allocetra
Enlivex is cutting 60% of its workforce and slashing executive salaries to secure funding for its Phase 2b trial of allocetra in knee osteoarthritis.
Marengo Therapeutics Receives Second FDA Fast Track for Invikafusp Alfa
The FDA granted a second Fast Track Designation to Marengo Therapeutics' invikafusp alfa for the treatment of TMB-H solid tumors.
Phanes Therapeutics Doses First CRC Patient in Spevatamig Clinical Study
Phanes Therapeutics announced the dosing of the first colorectal cancer patient in the Phase I/II clinical trial of the bispecific antibody spevatamig.
FDA’s Latest Rare Disease Framework Seeks Consistency and Flexibility
The FDA revealed a new framework to standardize clinical trial requirements across rare diseases, aiming to bring therapies to patients faster.
Multi-Cancer Blood Test Receives FDA Breakthrough Device Designation
Natera's multi-cancer early detection blood test, analyzing cell-free DNA to screen for multiple cancers, received FDA Breakthrough Device designation.
Sarepta Therapeutics Could Be 22% Undervalued Following Preclinical Data
Sarepta Therapeutics reveals preclinical data for SRP-1003 in myotonic dystrophy type 1, showing up to 80% knockdown of pathogenic DMPK RNA.
1
2
3
4
5
6
7
8
9